Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy

WILLIAMS, G.S., MISTRY, B., GUILLARD, S., ULRICHSEN, J.C., SANDERCOCK, A.M., WANG, J., GONZÁLEZ-MUÑOZ, A., PARMENTIER, J., BLACK, C., SODEN, J., FREETH, J., JOVANOVIC, J., LEYLAND, Rebecca, AL-LAMKI, R.S., LEISHMAN, A.J., RUST, S.J., STEWART, R., JERMUTUS, L., BRADLEY, J.R., BEDIAN, V., VALGE-ARCHER, V., MINTER, R. and WILKINSON, R.W. (2016). Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. Oncotarget, 7 (42), 68278-68291. [Article]

Documents
23187:517750
[thumbnail of Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.pdf]
Preview
PDF
Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.pdf - Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview
Abstract
© 2015. Oncotarget. Antibodies that target cell-surface molecules on T cells can enhance anti-tumor immune responses, resulting in sustained immune-mediated control of cancer. We set out to find new cancer immunotherapy targets by phenotypic screening on human regulatory T (Treg) cells and report the discovery of novel activators of tumor necrosis factor receptor 2 (TNFR2) and a potential role for this target in immunotherapy. A diverse phage display library was screened to find antibody mimetics with preferential binding to Treg cells, the most Treg-selective of which were all, without exception, found to bind specifically to TNFR2. A subset of these TNFR2 binders were found to agonise the receptor, inducing iκ-B degradation and NF-κB pathway signalling in vitro. TNFR2 was found to be expressed by tumor-infiltrating Treg cells, and to a lesser extent Teffcells, from three lung cancer patients, and a similar pattern was also observed in mice implanted with CT26 syngeneic tumors. In such animals, TNFR2-specific agonists inhibited tumor growth, enhanced tumor infiltration by CD8+ T cells and increased CD8+ T cell IFN-γ synthesis. Together, these data indicate a novel mechanism for TNF-α-independent TNFR2 agonism in cancer immunotherapy, and demonstrate the utility of target-agnostic screening in highlighting important targets during drug discovery.
More Information
Statistics

Downloads

Downloads per month over past year

Metrics

Altmetric Badge

Dimensions Badge

Share
Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email

Actions (login required)

View Item View Item